Ieq Capital LLC Grows Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Ieq Capital LLC grew its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 15.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 22,471 shares of the medical equipment provider's stock after buying an additional 3,033 shares during the quarter. Ieq Capital LLC's holdings in Intuitive Surgical were worth $7,581,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of ISRG. OFI Invest Asset Management purchased a new stake in Intuitive Surgical during the 3rd quarter valued at $25,000. Baystate Wealth Management LLC boosted its holdings in shares of Intuitive Surgical by 150.0% during the fourth quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 45 shares during the period. MCF Advisors LLC grew its stake in shares of Intuitive Surgical by 108.1% in the fourth quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider's stock worth $26,000 after purchasing an additional 40 shares during the last quarter. Headinvest LLC purchased a new position in Intuitive Surgical during the 3rd quarter valued at about $28,000. Finally, Stone House Investment Management LLC increased its holdings in Intuitive Surgical by 100.0% during the 3rd quarter. Stone House Investment Management LLC now owns 100 shares of the medical equipment provider's stock valued at $29,000 after purchasing an additional 50 shares during the period. Hedge funds and other institutional investors own 83.64% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ISRG. Barclays lifted their price objective on Intuitive Surgical from $385.00 to $430.00 and gave the stock an "overweight" rating in a research report on Thursday, January 25th. Truist Financial upped their price objective on shares of Intuitive Surgical from $390.00 to $435.00 and gave the stock a "buy" rating in a report on Wednesday, January 24th. Raymond James lifted their target price on shares of Intuitive Surgical from $372.00 to $435.00 and gave the company an "outperform" rating in a research note on Thursday, January 25th. Stifel Nicolaus boosted their price target on shares of Intuitive Surgical from $420.00 to $430.00 and gave the company a "buy" rating in a research report on Monday, April 8th. Finally, BTIG Research raised their price objective on shares of Intuitive Surgical from $412.00 to $421.00 and gave the stock a "buy" rating in a report on Friday, April 19th. Five research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, Intuitive Surgical has an average rating of "Moderate Buy" and a consensus target price of $396.17.

Insider Activity

In other news, EVP Robert Desantis sold 20,296 shares of the business's stock in a transaction on Friday, March 8th. The stock was sold at an average price of $393.80, for a total value of $7,992,564.80. Following the completion of the transaction, the executive vice president now owns 5,507 shares in the company, valued at $2,168,656.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, EVP Robert Desantis sold 20,296 shares of Intuitive Surgical stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $393.80, for a total value of $7,992,564.80. Following the completion of the sale, the executive vice president now directly owns 5,507 shares in the company, valued at $2,168,656.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Mark J. Rubash sold 1,709 shares of the business's stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $380.00, for a total transaction of $649,420.00. Following the transaction, the director now directly owns 16,051 shares of the company's stock, valued at $6,099,380. The disclosure for this sale can be found here. Insiders have sold a total of 147,927 shares of company stock worth $57,064,459 over the last 90 days. 0.90% of the stock is currently owned by insiders.

Intuitive Surgical Stock Up 0.3 %

Shares of NASDAQ ISRG traded up $1.25 during trading on Friday, reaching $386.70. The company had a trading volume of 853,114 shares, compared to its average volume of 1,440,851. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $403.76. The business's 50-day moving average is $384.98 and its 200 day moving average is $353.72. The stock has a market cap of $137.16 billion, a PE ratio of 69.80, a P/E/G ratio of 5.00 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, beating the consensus estimate of $1.40 by $0.10. The company had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. Intuitive Surgical's revenue for the quarter was up 11.5% on a year-over-year basis. During the same period in the prior year, the firm posted $1.00 EPS. On average, analysts anticipate that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.